Tango Therapeutics, Inc.

TNGX • Biotechnology

$22.52

— 0.00 (0.00%)

ResultadosÚltimo reporte: 30 jun 2026

PERFIL DÉBILDébilConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Perfil histórico débil. La evidencia actual no sostiene una relación riesgo/retorno favorable.

Capitalización

$3.38B

Crecimiento

11.3%

Flujo de caja

0/5

Tendencia

Negative

Evidencia

Nivel de deuda manejable · 0.1Liquidez saludable · 16.32Tendencia de crecimiento negativaRentabilidad débil

Datos financieros hasta: 30 jun 2026, 12:00 a.m. UTCÚltima actualización de earnings: 30 jun 2026, 12:00 a.m. UTCÚltima actualización del perfil: 13 ago 2026, 12:07 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$22.52

Change0.00%

Shares Out149.88M

Market Cap$3.38B

Enterprise Value$2.39B

52W Range6.25 - 34.39

Beta1.13

P/E-27.28

P/S62.72

P/B3.29

P/FCF-23.39

EV/Sales44.47

Price$22.52

Change0.00%

Shares Out149.88M

Market Cap$3.38B

Enterprise Value$2.39B

52W Range6.25 - 34.39

Beta1.13

P/E-27.28

P/S62.72

P/B3.29

P/FCF-23.39

EV/Sales44.47

EV/EBITDA-17.75

EV/FCF-16.59

Earnings Yield-3.67%

FCF Yield-4.27%

Dividend Yield0.00%

Gross Margin96.34%

Oper. Margin-178.39%

Profit Margin-162.85%

Debt/Eq0.10

Current Ratio16.32

Quick Ratio16.32

Revenue 5Y11.35%

Target$45.91

Target Upside103.86%

Target Median$40.00

Target Range24.00 - 69.00

Volume2.42M

Avg Volume3.65M

EPS Surprise0.00

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

22/100

Fortaleza financiera

Deuda, caja, estabilidad

76/100

Potencial de crecimiento

Ingresos y expansión

20/100

Atractivo del precio

Barata o cara hoy

49/100

Por qué este puntaje▼

Nivel de deuda manejable · 0.1Liquidez saludable · 16.32Tendencia de crecimiento negativaRentabilidad débil

Analyst view

Analyst sentiment and price target

TNGX

Analyst sentiment

Based on 13 analyst votes · 2026-09-05

96/100

Bullish

Hold

Bearish

Precio objetivo

2026-08-13

Bajo

$24.00

Promedio

$45.73

Mediana

$40.00

Alto

$69.00

Resumen de la compañía

IPO: 9/3/2020

Industria: Biotechnology

P/B i: 3.29

Deuda / Patrimonio i: 0.10

Margen operativo: -178.39%

Margen neto: -162.85%

ROE i: -

ROIC: -

Salud financiera

Puntaje15 / 20

Deuda / Patrimonio: 0.10

Ratio corriente: 16.32

Ratio rápido: 16.32

Estado: Good

Transacciones internas

Actividad reciente de ejecutivos e insiders

Crystal Adam

Transacción: 08/03/2026

VENTA

Cambio

-21,733

Precio

$27.35

Presentación

08/05/2026

Tipo

VENTA

Crystal Adam

Transacción: 08/03/2026

VENTA

Cambio

-27,000

Precio

$5.20

Presentación

08/05/2026

Tipo

VENTA

Crystal Adam

Transacción: 07/01/2026

VENTA

Cambio

-7,371

Precio

$30.25

Presentación

07/02/2026

Tipo

VENTA

Insider	Tipo	Cambio	Precio	Transacción	Presentación
Crystal Adam	VENTA	-21,733	$27.35	08/03/2026	08/05/2026
Crystal Adam	VENTA	-27,000	$5.20	08/03/2026	08/05/2026
Crystal Adam	VENTA	-7,371	$30.25	07/01/2026	07/02/2026
Crystal Adam	VENTA	-27,000	$5.20	07/01/2026	07/02/2026
Azelby Robert	OTRO	0	Not reported	06/19/2026	06/23/2026
Azelby Robert	COMPRA	+5,740	Not reported	06/19/2026	06/23/2026
Azelby Robert	COMPRA	+35,910	$27.97	06/19/2026	06/23/2026
Lee Sung	COMPRA	+3,570	$20.22	06/05/2026	06/08/2026
Lee Sung	COMPRA	+570	Not reported	06/05/2026	06/08/2026
Rothenberg Mace	COMPRA	+25,000	$20.22	06/05/2026	06/08/2026
Rothenberg Mace	COMPRA	+4,000	Not reported	06/05/2026	06/08/2026
Calhoun Lesley Ann	COMPRA	+4,000	Not reported	06/05/2026	06/08/2026
Calhoun Lesley Ann	COMPRA	+25,000	$20.22	06/05/2026	06/08/2026
Ketchum John B	COMPRA	+4,000	Not reported	06/05/2026	06/08/2026
Ketchum John B	COMPRA	+25,000	$20.22	06/05/2026	06/08/2026
Crystal Adam	VENTA	-20,860	$23.06	06/01/2026	06/03/2026
Crystal Adam	VENTA	-27,000	$5.20	06/01/2026	06/03/2026
Gall Matthew	COMPRA	+40,000	Not reported	05/01/2026	05/05/2026
Gall Matthew	COMPRA	+240,000	$20.98	05/01/2026	05/05/2026
Crystal Adam	VENTA	-1,100	$22.00	05/01/2026	05/05/2026

Sobre la compañía

Tango Therapeutics, Inc.

Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.

Fuente - Link

Competidores

BCAX EYPT FTRE KOD KURA NRIX PROK SEPN URGN XNCR

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX) (Tango Therapeutics or the Company) today announced that, effective September 1, 2026, the Compensation Committee of Tango Therapeutics' Board of Directors granted a non-qualified stock option to purchase 146,500 shares of its common stock and 40,000 restricted stock units (RSUs) to a new employee under Tango Therapeutics' 2023 Inducement Plan.

GlobeNewsWire

Tango Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX) (“Tango Therapeutics” or the “Company”) today announced that members of the management team are scheduled to participate in a fireside chat at the 2026 Cantor Global Healthcare Conference on Wednesday, September 9, 2026 at 8:35 AM EDT.

GlobeNewsWire

Algert Global LLC Grows Position in Tango Therapeutics, Inc. $TNGX

Algert Global LLC boosted its holdings in shares of Tango Therapeutics, Inc. (NASDAQ: TNGX) by 86.5% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 271,570 shares of the company's stock after purchasing an additional 125,930 shares during the

Defense World

Tango Therapeutics, Inc. $TNGX Shares Sold by Bank of America Corp DE

Bank of America Corp DE trimmed its stake in Tango Therapeutics, Inc. (NASDAQ: TNGX) by 31.6% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 327,144 shares of the company's stock after selling 150,918 shares during the quarter. Bank of

Defense World

ADAR1 Capital Management LLC Invests $2.40 Million in Tango Therapeutics, Inc. $TNGX

ADAR1 Capital Management LLC bought a new position in shares of Tango Therapeutics, Inc. (NASDAQ: TNGX) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund bought 76,761 shares of the company's stock, valued at approximately $2,400,000. A number of other institutional investors have also made

Defense World

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-05-13	-0.32	-0.32	0
2026-03-05	-0.31	-0.29	0.02
2025-11-04	0.01	0.13	0.12
2025-08-05	-0.35	-0.35	0
2025-05-12	-0.34	-0.36	-0.02
2025-02-27	-0.32	-0.35	-0.03
2024-11-06	-0.34	-0.27	0.07
2024-08-07	-0.34	-0.24	0.1
2024-05-08	-0.31	-0.35	-0.04
2024-03-18	-0.28	-0.32	-0.04
2023-11-08	-0.34	-0.23	0.11
2023-08-07	-0.35	-0.23	0.12